203, 2023 Prometheus Launches New Indication for PredictrPK® IFX, A Precision-Guided Dosing Test for IBDNicole Drago2023-03-02T07:05:24-08:002023-03-02| News & Events [...]Read More
1409, 2022 Prometheus Laboratories Announces Partnership with Takeda to Launch CDPATH™, a Personalized Prognostic Tool Advancing Innovation for Crohn’s Disease PatientsJudy Gohndrone2022-09-14T16:21:35-07:002022-09-14| News & Events [...]Read More
2202, 2022 Prometheus Laboratories Announces the Launch of PredictrPK® IFX, A Revolutionary Test Enabling Precision-Guided Dosing for Inflammatory Bowel Diseasenischal kashyap2022-09-29T16:12:57-07:002022-02-22| News & Events [...]Read More
1506, 2021 Prometheus Laboratories Announces New Agreement with MultiPlan, Expanding Patient Access to Specialized GI Testingprometheuslabs2021-11-15T02:14:33-08:002021-06-15| News & Events [...]Read More
1105, 2021 Prometheus Laboratories Announces Multiple Presentations on Precision-Guided Dosing and Monitoring at the Digestive Disease Week 2021 Annual Meetingprometheuslabs2021-11-15T02:09:44-08:002021-05-11| News & Events [...]Read More
